The Medical Letter on Drugs and Therapeutics
Fish Oil Supplements
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

The FDA has approved 2 products containing omega-3 polyunsaturated fatty acids (PUFAs) for treatment of patients with severe hypertriglyceridemia (>500 mg/dL). Lovaza (formerly Omacor) is available by prescription. The second FDA-approved omega-3 product, Vascepa, which contains only EPA, will not be available until 2013. Many other brands of fish oil capsules are sold over the counter (OTC) as dietary supplements; the US Pharmacopeia has verified that some of these contain their labeled content, are soluble in the body, and contain neither heavy metals nor contaminants.

CLINICAL STUDIES — Primary Prevention of Cardiovascular Disease – A mostly primary prevention trial (DOIT; Diet and Omega-3 Intervention Trial) in 563 high-risk elderly men treated with 2.4 g/d of n-3 PUFAs or corn oil for 3 years found that fatal and nonfatal cardiovascular events occurred in 32 of the 282 ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Fish Oil Supplements
Article code: 1401b
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian